<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00470600</url>
  </required_header>
  <id_info>
    <org_study_id>CPI-CL-008C</org_study_id>
    <nct_id>NCT00470600</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Caldolor (IV Ibuprofen) in Hospitalized Adult Orthopedic Patients</brief_title>
  <official_title>A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF IBUPROFEN INJECTION (IVIb) FOR TREATMENT OF PAIN IN POST-OPERATIVE ORTHOPEDIC ADULT PATIENTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cumberland Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cumberland Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study of Caldolor (IV ibuprofen) administered to post-operative
      hospitalized adult orthopedic patients every 6 hours for at least 24 hours is to determine
      the efficacy of Caldolor (IV ibuprofen) compared to placebo for the treatment of
      post-operative pain by patients self-assessment of pain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC-VAS With Movement (Post-operative Period, Hour-6-28)</measure>
    <time_frame>Study hour-6 through hour-28</time_frame>
    <description>Measurement of the patient's self assessment of pain with movement using the validated visual analog scale (VAS) during the post-operative period (study hour-6 through hour-28). VAS assessments document the patient's self reported level of pain from &quot;No pain&quot; (0 mm) to &quot;Worst possible pain&quot; (100 mm) on a 100 mm line. VAS assessments were performed immediately following surgery [variable since every surgery has a unique length of time even if it is the same procedure] and at hours 6, 8, 12, 16, 20, 24 and 28 (for the primary endpoint).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint: AUC-VAS at Rest (Post-operative Period, Hours 6-28)</measure>
    <time_frame>Study hour-6 through hour-28</time_frame>
    <description>Measurement of the patient's self assessment of pain at rest using a visual analog scale (VAS) during the post-operative period (study hour-6 through hour-28). VAS assessments document the patient's self reported level of pain from &quot;No pain&quot; (0 mm) to &quot;Worst possible pain&quot; (100 mm) on a 100 mm line. VAS assessments were performed immediately following surgery and at hours 6, 8, 12, 16, 20, 24 and 28 (for the primary endpoint).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Demand of Narcotic Use (Post-operative Period, From Hour 6 to 28).</measure>
    <time_frame>Study hour-6 to hour-28</time_frame>
    <description>Patient demand of narcotic used by patients in each treatment group for analgesia, post-surgery.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">185</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>250 milliliters normal saline as a placebo comparator was administered every 6 hours for a total of five doses over the first 24 hours. Those patients who received the initial five doses could continue to receive additional doses as needed every 6 hours through the 120-hour treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous ibuprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800 mg of intravenous ibuprofen diluted in 250 milliliters normal saline was administered every 6 hours for a total of five doses over the first 24 hours. Those patients who received the initial five doses could continue to receive additional doses as needed every 6 hours through the 120-hour treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caldolor</intervention_name>
    <description>800 milligrams intravenous</description>
    <arm_group_label>Intravenous ibuprofen</arm_group_label>
    <other_name>Ibuprofen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Normal Saline</arm_group_label>
    <other_name>NS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Scheduled for elective hip or knee replacement, reconstruction or arthroplasty surgery
             with anticipated need for post-operative intravenous (IV) morphine analgesia with
             anticipated use of (greater than or equal to (≥) 28 hours.

          2. Adequate IV access

          3. Anticipated hospital stay ≥ 28 hours

        Exclusion Criteria:

          1. Be unable to make a reliable self-report of pain intensity to pain relief

          2. Less than 18 years of age

          3. Greater than 80 years of age

          4. Use of analgesics, muscle relaxants, NSAIDS and sedatives less than 12 hours prior to
             clinicaltrial material(CTM) administration with the following exceptions: paracetamol
             (acetaminophen) can be administered until 6 hours prior to surgery; tramadol can be
             administered until midnight the evening prior to surgery; muscle relaxants working at
             the neuromuscular junction used for intubation and/or anesthesia administration for
             the surgical procedure prior to CTM administration; and sedatives (i.e., midazolam)
             used as a co-induction agent for the surgical procedure prior to CTM administration

          5. Patients taking warfarin, lithium, combination of angiotension converting
             enzyme(ACE)-inhibitors and furosemide

          6. Patients with anemia (active, clinically significant anemia) and/or a history or
             evidence of asthma or heart failure

          7. History of allergy or hypersensitivity to any component of Caldolor, aspirin (or
             aspirin related products), NSAIDs, or COX-2 inhibitors

          8. Pregnant or nursing

          9. History of severe head trauma that required current hospitalization, intracranial
             surgery or stroke within the previous 30 days, or any history of intracerebral
             arteriovenous malformation, cerebral aneurysm or CNS mass lesion

         10. Weigh less than 30 kilogram

         11. Have a history of congenital bleeding diathesis (e.g. hemophilia) or any active
             clinically significant bleeding, or have underlying platelet dysfunction including
             (but not limited to) idiopathic thrombocytopenic purpura, disseminated intravascular
             coagulation, or congenital platelet dysfunction

         12. Have gastrointestional (GI) bleeding that required medical intervention within the
             previous 6 weeks (unless definitive surgery has been performed)

         13. Have a platelet count less than 30,000 mm^3 determined within the 28 days prior to
             surgery

         14. Pre-existing dependence on narcotics or known tolerance to opioids

         15. Inability to understand the requirements of the study, be willing to provide written
             informed consent (as evidenced by signature on an informed consent document approved
             by an Institutional Review Board [IRB]), and agree to abide by the study restrictions
             and to return for the required assessments

         16. Refusal to provide written authorization for use and disclosure of protected health
             information

         17. Be on dialysis, have oliguria or creatinine greater than 3.0 milligram/deciliter.

         18. Inability to achieve hemostasis or inability to close surgical incision, prior to
             Operating Room discharge

         19. Operative procedure includes organ transplant

         20. Pre or intra-operative procedure utilized for the prevention of pre- or post-operative
             pain (i.e. epidural or nerve blocks)

         21. Be receiving full dose anticoagulation therapy or Activated Protein C within 6 hours
             before dosing (Prophylaxis with subcutaneous heparin is acceptable)

         22. Have received another investigational drug within the past 30 days

         23. Be otherwise unsuitable for the study in the opinion of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Singla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lotus Clinical Research/Methodist Hospital of Southern CA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wilmax Clinical Research Inc.</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>336608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teton Research, LLC</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Management Services, Inc.</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Center for Clinical Trials</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Concepts, Inc</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Concepts, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannesburg General Hospital</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krugersdorp Private Hospital</name>
      <address>
        <city>Krugersdorp</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eugene Marais Hospital</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2007</study_first_submitted>
  <study_first_submitted_qc>May 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2007</study_first_posted>
  <results_first_submitted>April 7, 2011</results_first_submitted>
  <results_first_submitted_qc>November 3, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 8, 2011</results_first_posted>
  <last_update_submitted>August 3, 2015</last_update_submitted>
  <last_update_submitted_qc>August 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>250 mL of normal saline.</description>
        </group>
        <group group_id="P2">
          <title>800mg IV Ibuprofen (Caldolor)</title>
          <description>8 mL of IV Ibuprofen (Caldolor) added with 250 mL of normal saline to give 800 mg dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="86">Two subjects were randomized to incorrect stratification categories (weight).</participants>
                <participants group_id="P2" count="99">One subject was randomized to incorrect stratification categories (weight).</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>250 mL of normal saline.</description>
        </group>
        <group group_id="B2">
          <title>800mg IV Ibuprofen (Caldolor)</title>
          <description>8 mL of IV Ibuprofen (Caldolor) added with 250 mL of normal saline to give 800 mg dose.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="86"/>
            <count group_id="B2" value="99"/>
            <count group_id="B3" value="185"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" spread="9.9"/>
                    <measurement group_id="B2" value="62" spread="10.3"/>
                    <measurement group_id="B3" value="61" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;45years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 45 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC-VAS With Movement (Post-operative Period, Hour-6-28)</title>
        <description>Measurement of the patient’s self assessment of pain with movement using the validated visual analog scale (VAS) during the post-operative period (study hour-6 through hour-28). VAS assessments document the patient's self reported level of pain from &quot;No pain&quot; (0 mm) to &quot;Worst possible pain&quot; (100 mm) on a 100 mm line. VAS assessments were performed immediately following surgery [variable since every surgery has a unique length of time even if it is the same procedure] and at hours 6, 8, 12, 16, 20, 24 and 28 (for the primary endpoint).</description>
        <time_frame>Study hour-6 through hour-28</time_frame>
        <population>Efficacy analyses were performed on the Intent to Treat (ITT) population and the Efficacy Evaluable Population (EEP). All randomized patients who received at least a partial dose of CTM were included in the ITT analyses. All data below represents the ITT analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>250 mL of normal saline.</description>
          </group>
          <group group_id="O2">
            <title>800mg IV Ibuprofen (Caldolor)</title>
            <description>8 mL of IV Ibuprofen (Caldolor) added with 250 mL of normal saline to give 800 mg dose.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC-VAS With Movement (Post-operative Period, Hour-6-28)</title>
          <description>Measurement of the patient’s self assessment of pain with movement using the validated visual analog scale (VAS) during the post-operative period (study hour-6 through hour-28). VAS assessments document the patient's self reported level of pain from &quot;No pain&quot; (0 mm) to &quot;Worst possible pain&quot; (100 mm) on a 100 mm line. VAS assessments were performed immediately following surgery [variable since every surgery has a unique length of time even if it is the same procedure] and at hours 6, 8, 12, 16, 20, 24 and 28 (for the primary endpoint).</description>
          <population>Efficacy analyses were performed on the Intent to Treat (ITT) population and the Efficacy Evaluable Population (EEP). All randomized patients who received at least a partial dose of CTM were included in the ITT analyses. All data below represents the ITT analyses.</population>
          <units>AUC-VAS pain v. time (mm*hr)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1326.1" spread="82.0"/>
                    <measurement group_id="O2" value="1005.0" spread="81.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Endpoint: AUC-VAS at Rest (Post-operative Period, Hours 6-28)</title>
        <description>Measurement of the patient’s self assessment of pain at rest using a visual analog scale (VAS) during the post-operative period (study hour-6 through hour-28). VAS assessments document the patient's self reported level of pain from &quot;No pain&quot; (0 mm) to &quot;Worst possible pain&quot; (100 mm) on a 100 mm line. VAS assessments were performed immediately following surgery and at hours 6, 8, 12, 16, 20, 24 and 28 (for the primary endpoint).</description>
        <time_frame>Study hour-6 through hour-28</time_frame>
        <population>Efficacy analyses were performed on the Intent to Treat (ITT) population and the Efficacy Evaluable Population (EEP). All randomized patients who received at least a partial dose of CTM were included in the ITT analyses. All data below represents the ITT analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>250 mL of normal saline.</description>
          </group>
          <group group_id="O2">
            <title>800mg IV Ibuprofen (Caldolor)</title>
            <description>8 mL of IV Ibuprofen (Caldolor) added with 250 mL of normal saline to give 800 mg dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Endpoint: AUC-VAS at Rest (Post-operative Period, Hours 6-28)</title>
          <description>Measurement of the patient’s self assessment of pain at rest using a visual analog scale (VAS) during the post-operative period (study hour-6 through hour-28). VAS assessments document the patient's self reported level of pain from &quot;No pain&quot; (0 mm) to &quot;Worst possible pain&quot; (100 mm) on a 100 mm line. VAS assessments were performed immediately following surgery and at hours 6, 8, 12, 16, 20, 24 and 28 (for the primary endpoint).</description>
          <population>Efficacy analyses were performed on the Intent to Treat (ITT) population and the Efficacy Evaluable Population (EEP). All randomized patients who received at least a partial dose of CTM were included in the ITT analyses. All data below represents the ITT analyses.</population>
          <units>AUC-VAS pain v. time (mm*hr)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="997.0" spread="83.6"/>
                    <measurement group_id="O2" value="728.0" spread="83.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Demand of Narcotic Use (Post-operative Period, From Hour 6 to 28).</title>
        <description>Patient demand of narcotic used by patients in each treatment group for analgesia, post-surgery.</description>
        <time_frame>Study hour-6 to hour-28</time_frame>
        <population>Demand of narcotic use was determined by PCA records or by chart if patient requested and not via PCA.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>250 mL of normal saline.</description>
          </group>
          <group group_id="O2">
            <title>800mg IV Ibuprofen (Caldolor)</title>
            <description>8 mL of IV Ibuprofen (Caldolor) added with 250 mL of normal saline to give 800 mg dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Demand of Narcotic Use (Post-operative Period, From Hour 6 to 28).</title>
          <description>Patient demand of narcotic used by patients in each treatment group for analgesia, post-surgery.</description>
          <population>Demand of narcotic use was determined by PCA records or by chart if patient requested and not via PCA.</population>
          <units>milligrams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.5" spread="29.9"/>
                    <measurement group_id="O2" value="41.1" spread="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>250 mL of normal saline.</description>
        </group>
        <group group_id="E2">
          <title>800mg IV Ibuprofen (Caldolor)</title>
          <description>8 mL of IV Ibuprofen (Caldolor) added with 250 mL of normal saline to give 800 mg dose.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Post procedural pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Altered mental status</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="86"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="86"/>
                <counts group_id="E2" events="28" subjects_affected="27" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="86"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="37" subjects_affected="30" subjects_at_risk="86"/>
                <counts group_id="E2" events="47" subjects_affected="44" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="86"/>
                <counts group_id="E2" events="18" subjects_affected="14" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>anaemia postoperative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="86"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="86"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Haemaglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="86"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="86"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="22" subjects_affected="17" subjects_at_risk="86"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="86"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amy Rock, Ph.D.</name_or_title>
      <organization>Cumberland Pharmaceuticals</organization>
      <phone>615-255-0068</phone>
      <email>arock@cumberlandpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

